DiaSys Enters Costa Rican Market Through Distribution Agreement with Largest Clinical Diagnostics Distributor in the Country; Company Enters Additional Market in Latin America.

WATERBURY, Conn. -- DiaSys Corporation (AMEX:DYX) a global diagnostics products company, announced today that it has entered into a distribution agreement with Tecnodiagnsostica, the largest distributor of clinical diagnostic products in Costa Rica. Founded in 1985, Tecnodiagnostica is the exclusive distributor in the country for Beckmann Coulter Inc., Olympus, bioMerieux, Meridian Diagnostics Inc. and other leading providers of diagnostics products. Costa Rica represents the second key market in Latin America that DiaSys has entered in the past week. Previously, the Company announced that it had entered Latin America through a distribution agreement with Repreclin S.A.

"Costa Rica represents an important opportunity for us," said Jose Puig, DiaSys Corporation's Sales Manager for Latin America. "We believe based on the significant infrastructure already in place through Tecnodiagnostica that we can rapidly increase sales of our products. The market for parasite and urine testing is particularly well suited for our products. Based upon the success that the company has achieved representing other leading providers of diagnostics products, we feel that the combination of our innovative product lines and their distribution will enable us to rapidly penetrate the market."

Tecnodiagnostica has close to 700 diagnostic instruments installed in the country. The Costa Rica Social Security agency performs over one million parasite tests annually, and close to three million urine tests per year.

DiaSys Corporation designs, develops, manufactures and distributes proprietary medical laboratory equipment, consumables and infectious disease test kits to healthcare and veterinary laboratories worldwide. Headquartered in Waterbury, Connecticut, the Company operates in Europe through its wholly owned subsidiary based in Wokingham, England. DiaSys, Parasep and Urisep are registered trademarks of DiaSys Corporation.

This press release contains forward-looking statements within the meaning of, and made pursuant to, the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or events, or timing of events, relating to the Company to materially differ from those expressed or implied by such forward looking statements. DiaSys refers interested parties to its most recent Annual Report on form 10-KSB and other SEC filings for a complete description of, and discussions about, the company.